ASIANET: SCICLONE'S ZADAXIN(R) THYMOSIN ALPHA 1 IS EFFECTIVE AND SAFE...
* Statistically significant increase in conversion from both hepatitis B
virus positive to negative and hepatitis B e antigen positive to
negative.
At the end of the study, 40.6% of patients receiving 1.6 mg of ZADAXIN
twice per week for 26 weeks tested negative for both hepatitis B virus
and hepatitis B e antigen (an immune response to the hepatitis B virus
that can indicate long lasting remission of the disease) compared to
9.4% of patients in the control group, a statistically significant
result (p=.004).
* Statistically significant histological improvement.
Patients responding to ZADAXIN showed statistically significant
improvement in liver histology (inflammation of the liver) (p<.05),
consistent with the ultimate goals of therapy for hepatitis B -- to
prevent progression to serious liver disease, including liver cancer and
cirrhosis.
* Experienced no significant side effects.
ข่าวSciClone Pharmaceuticals+PRNewswireวันนี้
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU(R) (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of resistance to standard endocrine therapy, making these tumors more difficult to treat. This agreement includes undisclosed upfront, milestone payments
Korea's representative blockchain-based loyalty integration platform MiL.K, unlocks Indonesia market with GetPlus, a leading coalition loyalty program
—
Milk Partne...